Evidence map›Paper›PMID 40284664›Full record

ArticleMicroorganisms2025

Amebicidal Activity of

Vivian Moura-Oliveira, Fabrício M S Oliveira, Olga L M Moreno, Julia R Ferreira, Raphael E Szawka, Ana C Campideli-Santana, Jullia Teles, Luciano S A Capettini, Flaviano S Martins, Maria A Gomes

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microorganisms, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Vivian Moura-OliveiraDepartment of Parasitology, Federal University of Minas Gerais, Belo Horizonte 31270-901, MG, Brazil.ORCID 0000-0001-6454-630X
Fabrício M S OliveiraTranslational Type 2 Immunity Laboratory, Microbiology, Immunology and Tropical Medicine Department, George Washington School of Medicine and Health Sciences, Washington, DC 20052, USA.ORCID 0000-0001-9963-1758
Olga L M MorenoDepartment of Pharmacology, Federal University of Minas Gerais, Belo Horizonte 31270-901, MG, Brazil.
Julia R FerreiraDepartment of Parasitology, Federal University of Minas Gerais, Belo Horizonte 31270-901, MG, Brazil.
Raphael E SzawkaDepartment of Physiology and Biophysics, Federal University of Minas Gerais, Belo Horizonte 31270-901, MG, Brazil.ORCID 0000-0002-2639-3469
Ana C Campideli-SantanaDepartment of Physiology and Biophysics, Federal University of Minas Gerais, Belo Horizonte 31270-901, MG, Brazil.ORCID 0000-0001-5225-4940
Jullia TelesDepartment of Parasitology, Federal University of Minas Gerais, Belo Horizonte 31270-901, MG, Brazil.
Luciano S A CapettiniDepartment of Pharmacology, Federal University of Minas Gerais, Belo Horizonte 31270-901, MG, Brazil.
Flaviano S MartinsDepartment of Microbiology, Federal University of Minas Gerais, Belo Horizonte 31270-901, MG, Brazil.ORCID 0000-0003-0741-3062
Maria A GomesDepartment of Parasitology, Federal University of Minas Gerais, Belo Horizonte 31270-901, MG, Brazil.ORCID 0000-0002-7263-5721

Funding

FAPEMIG APQ-02829-18FAPEMIG and CNPq BPQ-06575-24
6 · The paper itself

Abstract

Amebiasis is a globally prevalent infection that can lead to fatal outcomes if not adequately treated. Conventional treatment with imidazoles often fails due to side effects and resistance, emphasizing the need for alternative therapies. The probiotic

Indexed as

Entamoeba histolyticaEscherichia coliNissleprobioticreactive oxygen species

Identifiers

PMID40284664
PMCPMC12029587

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.